--- title: "SINOPHARM stated that there are no plans for large-scale store closures this year, as health consumption has become a necessity" type: "News" locale: "en" url: "https://longbridge.com/en/news/280110094.md" description: "Sinopharm (1099) Vice President Wu Yijian stated that there are no plans for large-scale store closures this year, focusing instead on enhancing community health services. Last year, the number of Guoda pharmacies decreased to 8,221, and the number of professional pharmacies decreased to 1,461. Director Zhao Bingxiang pointed out that 7 million people will retire in the next 15 years, and the rigid medical demand will drive market growth. Sinopharm's net profit last year was 7.155 billion yuan, with revenue of 575.168 billion yuan, and the gross profit margin decreased to 7.25%" datetime: "2026-03-23T06:37:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280110094.md) - [en](https://longbridge.com/en/news/280110094.md) - [zh-HK](https://longbridge.com/zh-HK/news/280110094.md) --- # SINOPHARM stated that there are no plans for large-scale store closures this year, as health consumption has become a necessity SINOPHARM (1099) has reduced approximately 2,000 directly operated stores over the past year and a half. Vice President and Board Secretary Eric Wu stated that there are no plans for large-scale store closures this year, and it remains a year for quality improvement and efficiency enhancement. He also mentioned that the total scale of Guoda Pharmacy and SPS+ Pharmacy is currently stable at around 10,000 stores, focusing entirely on community health services and the core scenario of prescription outflow around hospitals. ## Last Year, 1,348 Stores Reduced The group announced that as of the end of last year, the number of Guoda pharmacies was 8,221, a net decrease of 1,348 stores compared to the same period last year; the number of professional pharmacy stores was 1,461, a decrease of 183 stores compared to the same period last year. Regarding the aging population, Director and General Manager Zhao Bingxiang stated that approximately 7 million people will enter retirement each year over the next 15 years, with rigid medical demand continuing to be released, becoming the most certain growth driver in the pharmaceutical market. He also pointed out that residents' health awareness and payment ability are improving simultaneously, with per capita health expenditure accounting for 15.6% of disposable income, making health consumption a necessity. Looking ahead, Zhao Bingxiang expects that the overall market will remain stable, showing a trend of steady growth and structural optimization by 2026. He continued to emphasize the importance of leveraging network advantages, continuously optimizing distribution and logistics systems, selectively carrying out mergers and acquisitions, and simultaneously cleaning up inefficient assets and non-core businesses to ensure stable and orderly operational development. ## Last Year, Profit Increased by 1.5% and Dividend Increased by Nearly 15% SINOPHARM announced its annual results for the year ending last year, with a net profit of RMB 7.155 billion, an increase of 1.5% year-on-year; earnings per share increased by 1.3% year-on-year to RMB 2.29, with a final dividend of RMB 0.69, an increase of 14.7% year-on-year. During the period, revenue was RMB 575.168 billion, a year-on-year decrease of 1.6%, mainly due to a decline in revenue from the group's pharmaceutical distribution, medical device distribution business, and other business segments; gross profit margin decreased by 0.32 percentage points year-on-year to 7.25% ### Related Stocks - [600511.CN](https://longbridge.com/en/quote/600511.CN.md) - [000028.CN](https://longbridge.com/en/quote/000028.CN.md) - [01099.HK](https://longbridge.com/en/quote/01099.HK.md) - [159898.CN](https://longbridge.com/en/quote/159898.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [562600.CN](https://longbridge.com/en/quote/562600.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159883.CN](https://longbridge.com/en/quote/159883.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) ## Related News & Research - [Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base](https://longbridge.com/en/news/284128644.md) - [Sinopharm Group Co (SHTDF) Gets a Buy from CLSA](https://longbridge.com/en/news/284466436.md) - [Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.](https://longbridge.com/en/news/284379502.md) - [Sinopharm subsidiary posts steady Q1 profit growth but cash flow weakens](https://longbridge.com/en/news/283669573.md) - [CMS extends application deadlines for Medicaid drug pricing model](https://longbridge.com/en/news/284622334.md)